| Literature DB >> 13680286 |
Katsuki Ito1, Hiroaki Nakazato, Akihiko Koike, Hiroshi Takagi, Shigetoyo Saji, Shozo Baba, Masayoshi Mai, Jun-ichi Sakamoto, Yasuo Ohashi.
Abstract
BACKGROUND AND AIMS: The efficacy of a biological response modifier polysaccharide K in adjuvant immunochemotherapy was evaluated in primary colon cancer patients with macroscopic Dukes' C after curative resection. PATIENTS AND METHODS: Employing the minimization method using three factors (lymph node metastases, preoperative serum CEA level, and institution), 446 patients were allocated into groups P and C. Group P received immunochemotherapy, oral PSK (3 g per day) followed by oral 5-FU (200 mg/body per day), while group C received only intermittent chemotherapy, oral 5-FU (200 mg per day) followed by 4-week rest. Both groups received ten courses.Entities:
Mesh:
Substances:
Year: 2003 PMID: 13680286 DOI: 10.1007/s00384-003-0532-x
Source DB: PubMed Journal: Int J Colorectal Dis ISSN: 0179-1958 Impact factor: 2.571